X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (91) 91
male (69) 69
female (66) 66
oncology (66) 66
aged (62) 62
middle aged (56) 56
index medicus (42) 42
aged, 80 and over (36) 36
adult (34) 34
lung cancer (31) 31
lung neoplasms - drug therapy (29) 29
mesothelioma (23) 23
cancer (22) 22
lung neoplasms - pathology (22) 22
diagnosis (21) 21
prognosis (20) 20
respiratory system (20) 20
chemotherapy (18) 18
asbestos (17) 17
carcinoma, non-small-cell lung - drug therapy (16) 16
lung neoplasms - mortality (16) 16
cisplatin (15) 15
gefitinib (14) 14
lung neoplasms - genetics (14) 14
mesothelioma - pathology (14) 14
survival (14) 14
non-small cell lung cancer (13) 13
research (13) 13
retrospective studies (13) 13
treatment outcome (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
lung cancer, non-small cell (12) 12
mutation (12) 12
tumors (12) 12
expression (11) 11
medicine, general & internal (11) 11
pleural fluid (11) 11
survival analysis (11) 11
antineoplastic agents - therapeutic use (10) 10
immunohistochemistry (10) 10
neoplasm staging (10) 10
survival rate (10) 10
carcinoma, non-small-cell lung - mortality (9) 9
combination (9) 9
hematology, oncology and palliative medicine (9) 9
japan - epidemiology (9) 9
lung neoplasms - diagnosis (9) 9
carcinoma, non-small-cell lung - genetics (8) 8
care and treatment (8) 8
dna methylation (8) 8
erlotinib (8) 8
japan (8) 8
medicine & public health (8) 8
mesothelioma - diagnosis (8) 8
methylation (8) 8
oncology, experimental (8) 8
pleural mesothelioma (8) 8
pulmonary/respiratory (8) 8
receptor, epidermal growth factor - genetics (8) 8
biomarkers, tumor - metabolism (7) 7
carcinoma, non-small-cell lung - pathology (7) 7
cell line, tumor (7) 7
cells (7) 7
gene (7) 7
lung-cancer (7) 7
mesothelioma - mortality (7) 7
mutations (7) 7
pleural neoplasms - pathology (7) 7
quinazolines - therapeutic use (7) 7
radiotherapy (7) 7
tomography, x-ray computed (7) 7
adenocarcinoma - drug therapy (6) 6
analysis (6) 6
carcinoma (6) 6
diagnosis, differential (6) 6
drug resistance, neoplasm (6) 6
effusion (6) 6
genetic aspects (6) 6
lung neoplasms - metabolism (6) 6
malignant pleural mesothelioma (6) 6
medicine, research & experimental (6) 6
metastasis (6) 6
original (6) 6
quality of life (6) 6
risk factors (6) 6
studies (6) 6
tumor cells, cultured (6) 6
adenocarcinoma (5) 5
adolescent (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
breast-cancer (5) 5
cancer therapies (5) 5
carboplatin (5) 5
carcinomas (5) 5
cell proliferation (5) 5
cisplatin - administration & dosage (5) 5
clinical trials (5) 5
disease (5) 5
disease progression (5) 5
egfr (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Science, ISSN 1347-9032, 02/2016, Volume 107, Issue 2, pp. 162 - 167
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 8/2016, Volume 24, Issue 8, pp. 3473 - 3480
Journal Article
Proceedings of the National Academy of Sciences, ISSN 0027-8424, 07/2012, Volume 109, Issue 31, pp. E2127 - E2133
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 8/2016, Volume 24, Issue 8, pp. 3495 - 3505
Journal Article
by Mok, Tony and Mok, Tony S K and Wu, Yilong and Wu, Yi-Long and Kudaba, Iveta and Kowalski, Dariusz M and Kowalski, Dariusz and Cho, Byoung Chul and Turna, Hande and Turna, Hande Z and Castro, Hugo and Castro, Gilberto and Srimuninnimit, Vichien and Laktionov, Konstantin and Laktionov, Konstantin K and Bondarenko, Igor and Kubota, Kaoru and Lubiniecki, Gregory M and Zhang, Jin and Zhang, Li and Zhang, Xin and Kush, Debra and Lopes, Valeria and Lopes, Gilberto and Adamchuk, Grigory and Ahn, Myung-Ju and Alexandru, Aurelia and Altundag, Ozden and Alyasova, Anna and Andrusenko, Orest and Aoe, Keisuke and Araujo, Antonio and Aren, Osvaldo and Arrieta Rodriguez, Oscar and Ativitavas, Touch and Avendano, Oscar and Barata, Fernando and Barrios, Carlos Henrique and Beato, Carlos and Bergstrom, Per and Betticher, Daniel and Bolotina, Larisa and Botha, Michiel and Buddu, Sayeuri and Caglevic, Christian and Cardona, Andres and Cay Senler, Filiz and Cerny, Carlos Alexandre Sydow and Cesas, Alvydas and Chan, Gee-Chen and Chang, Jianhua and Chen, Xi and Chen, Gongyan and Cheng, Ying and Cheng, Susanna and Cherciu, Nelly and Chiu, Chao-Hua and Cicenas, Saulius and Ciurescu, Daniel and Cohen, Graham and Costa, Marcos Andre and Danchaivijitr, Pongwut and De Angelis, Flavia and de Azevedo, Sergio Jobim and Dediu, Mircea and Deliverski, Tsvetan and De Marchi, Pedro Rafael Martins and de The Bustamante Valles, Flor and Ding, Zhenyu and Doganov, Boyan and Dreosti, Lydia and Duarte, Ricardo and Edusma-Dy, Regina and Emelyanov, Sergey and Erman, Mustafa and Fan, Yun and Fein, Luis and Feng, Jifeng and Fenton, David and Fernandes, Gustavo and Ferreira, Carlos and Franke, Fabio Andre and Freitas, Helano and Fujisaka, Yasuhito and Galindo, Hector and Galvez, Christina and Ganea, Doina and Gil, Nuno and Girotto, Gustavo and Goker, Erdem and Goksel, Tuncay and Gomez Aubin, Gonzalo and Gomez Wolff, Luis and Griph, Hakan and Gumus, Mahmut and Hall, Jacqueline and Hart, Gregory and Havel, Libor and He, Yong and He, Jianxing and ... and KEYNOTE-042 Investigators
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10183, pp. 1819 - 1830
First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a... 
MEDICINE, GENERAL & INTERNAL | CARBOPLATIN | GEFITINIB | BEVACIZUMAB | CRIZOTINIB | NIVOLUMAB | PACLITAXEL | Genes, erbB-1 - drug effects | Lung Neoplasms - drug therapy | Translocation, Genetic | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Lung Neoplasms - metabolism | Middle Aged | Far East - epidemiology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Anaplastic Lymphoma Kinase - genetics | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Non-Small-Cell Lung - secondary | Lung Neoplasms - secondary | Female | Carcinoma, Non-Small-Cell Lung - pathology | Anaplastic Lymphoma Kinase - drug effects | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Genes, erbB-1 - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Disease-Free Survival | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm Metastasis - pathology | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Chemotherapy | Metastasis | Lung cancer, Non-small cell | Cancer | Slopes | Lung cancer | Oncology | Kinases | Cancer therapies | Metastases | Pembrolizumab | Randomization | Motivation | Platinum | Risk assessment | Population | Translocation | Cell survival | Life expectancy | Epidermal growth factor receptors | Hyperthyroidism | Histology | Hypothyroidism | Survival | Patients | Medical centres | Life span | Interactive systems | PD-L1 protein | Men | Ligands | Tumors | Apoptosis
Journal Article
Cancer, ISSN 0008-543X, 02/2018, Volume 124, Issue 3, pp. 606 - 616
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_6
Abstract Background In December 2015, nivolumab was approved as treatment for previously treated NSCLC irrespective of PD-L1 expression or histology in Japan.... 
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_6
Abstract Background In December 2015, nivolumab was approved for previously treated advanced NSCLC irrespective of PD-L1 expression or histology in Japan.... 
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_6
Abstract Background In December 2015, nivolumab was approved as treatment for previously treated NSCLC irrespective of PD-L1 expression or histology in Japan.... 
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_6
Abstract Background Since its approval in December 2015, nivolumab has been widely used as a second-line treatment for non-small cell lung cancer (NSCLC)... 
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_6
Abstract Background Osimertinib is a key-drug to treat NSCLC harboring EGFR sensitizing mutation at 1st line setting as well as T790M resistant mutation at... 
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 1/2009, Volume 135, Issue 1, pp. 117 - 123
Journal Article
BMC CANCER, ISSN 1471-2407, 04/2019, Volume 19, Issue 1, pp. 383 - 7
BackgroundMalignant pleural mesothelioma (MPM) is a fatal and rare disease that is caused by the inhalation of asbestos. Treatment and care requests made by... 
PALLIATIVE CARE | Asbestos | Support | ONCOLOGY | Patient-centered care | Mesothelioma | EXPERIENCE | Communication
Journal Article
Cancer Science, ISSN 1347-9032, 03/2012, Volume 103, Issue 3, pp. 483 - 490
In the present study, malignant mesothelioma (MM) cases in Japan were investigated retrospectively. We extracted records for 6030 cases of death due to MM... 
PLEURAL MESOTHELIOMA | ONCOLOGY | DIAGNOSIS | Japan - epidemiology | Mesothelioma - pathology | Humans | Mesothelioma - chemically induced | Middle Aged | Male | Young Adult | Adolescent | Aged, 80 and over | Asbestos - adverse effects | Mesothelioma - epidemiology | Adult | Female | Aged
Journal Article